46. 悪性関節リウマチ [臨床試験数:4,183,薬物数:2,538(DrugBank:401),標的遺伝子数:183,標的パスウェイ数:219

Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
11 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-015740-42-DE12/05/201012/01/2010A PHASE 3, MULTICENTER, RANDOMIZED, OPEN, PROSPECTIVE, CONTROLLED, PARALLEL-GROUP STUDY OF REDUCTION OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ONGOING REMISSIONRETRO – REduction of Therapy in RA patients in Ongoing remission,Reduzierung der Therapie bei RA-Patienten in Remission - RETROA PHASE 3, MULTICENTER, RANDOMIZED, OPEN, PROSPECTIVE, CONTROLLED, PARALLEL-GROUP STUDY OF REDUCTION OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ONGOING REMISSIONRETRO – REduction of Therapy in RA patients in Ongoing remission,Reduzierung der Therapie bei RA-Patienten in Remission - RETRO Rheumatoid arthritis
MedDRA version: 17.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
Product Name: Prednisolon
Product Code: Prednisolon
INN or Proposed INN: PREDNISOLONE
Trade Name: Humira
INN or Proposed INN: ADALIMUMAB
Product Name: Azathioprin
Other descriptive name: AZATHIOPRINE
Trade Name: Immunosporin
Product Name: Immunosporin
INN or Proposed INN: CICLOSPORIN
Trade Name: Cimzia
Product Name: Cimzia
INN or Proposed INN: GOLIMUMAB
Trade Name: Enbrel
Product Name: Enbrel
INN or Proposed INN: ETANERCEPT
Product Name: Quensyl
Other descriptive name: HYDROXYCHLOROQUINE SULFATE
Trade Name: REMICADE
Product Name: Remicade
INN or Proposed INN: INFLIXIMAB
Trade Name: Lantarel
Product Name: Lantarel
INN or Proposed INN: METHOTREXATE SODIUM
Other descriptive name: Lantarel
Trade Name: Arava
Product Name: Arava
INN or Proposed INN: LEFLUNOMIDE
Other descriptive name: Arava
Product Name: Metex 2,5mg
INN or Proposed INN: METHOTREXATE SODIUM
Other descriptive name: Metex 2,5mg
Universitätsklinkum ErlangenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 3Germany
2EUCTR2007-001377-28-PT09/01/200925/08/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLNot RecruitingFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria
3EUCTR2007-001377-28-DE01/09/200815/05/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLNot RecruitingFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria
4EUCTR2007-001377-28-NL15/07/200829/05/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLNot RecruitingFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria
5EUCTR2007-001377-28-AT26/06/200827/05/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLNot RecruitingFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2007-001377-28-FR11/06/200829/02/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria
7EUCTR2007-001984-31-IT28/09/200717/12/2007A PHASE 2 RANDOMIZED, MULTICENTER, ACTIVE COMPARATOR-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF COADMINISTRATION OF CP-690,550 AND MYCOPHENOLATE MOFETIL / MYCOPHENOLATE SODIUM IN DE NOVO KIDNEY ALLOGRAFT RECIPIENTS - NDA PHASE 2 RANDOMIZED, MULTICENTER, ACTIVE COMPARATOR-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF COADMINISTRATION OF CP-690,550 AND MYCOPHENOLATE MOFETIL / MYCOPHENOLATE SODIUM IN DE NOVO KIDNEY ALLOGRAFT RECIPIENTS - ND CP-690,550 is an immunosuppressive agent being developed for the prevention of kidney allograft rejection, and for the treatment of rheumatoid arthritis as a disease-modifying anti-rheumatic drug.
MedDRA version: 9.1Level: LLTClassification code 10023439Term: Kidney transplant rejection
Product Name: CP-690,550
Product Name: CP-690,550
Trade Name: SANDIMMUN NEORAL*50CPS 25MG
INN or Proposed INN: Ciclosporin
Trade Name: SANDIMMUN NEORAL*30CPS 100MG
INN or Proposed INN: Ciclosporin
PFIZERNULLNot RecruitingFemale: yes
Male: yes
300Phase 2Portugal;Germany;Czech Republic;Netherlands;Belgium;France;Spain;Italy
8NCT00521924June 200727/8/2007Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab-therapyRheumatoid ArthritisBiological: infliximab;Drug: DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.Merck Sharp & Dohme Corp.AESCA Pharma GmbHTerminated19 Years65 YearsAll8Phase 3Austria
9EUCTR2007-001190-28-GB09/05/200717/04/2007Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis - TACITRandomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis - TACIT Rheumatoid Arthritis
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
Product Name: Methotrexate
Product Code: Methotrexate
INN or Proposed INN: METHOTREXATE
Product Name: Sulfasalazine
Product Code: Sulfasalazine
INN or Proposed INN: SULFASALAZINE
Product Name: Hydroxychloroquine
Product Code: Hydroxychloroquine
INN or Proposed INN: Hydroxychloroquine
Product Name: Ciclosporin
Product Code: Ciclosporin
INN or Proposed INN: Ciclosporin
Product Name: Leflunomide
Product Code: Leflunomide
INN or Proposed INN: Leflunomide
Product Name: Sodium aurothiomalate (intramuscular gold)
Product Code: Sodium aurothiomalate (intramuscular gold)
INN or Proposed INN: Sodium aurothiomalate
Product Name: methylprednisolone
Product Code: methylprednisolone
INN or Proposed INN: Methylprednisolone
Product Name: Prednisolone
Product Code: Predniso
King's College LondonNULLNot RecruitingFemale: yes
Male: yes
190Phase 4United Kingdom
10NCT00006055March 20005/7/2000Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune DiseasesPurpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu ArteritisDrug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell TransplantationFairview University Medical CenterNULLActive, not recruiting1 Year55 YearsBoth10N/AUnited States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00209859October 199816/9/2005Methotrexate and Cyclosporine in Treatment of Early Rheumatoid ArthritisCombination Treatment With Methotrexate and Cyclosporine in Early Rheumatoid Arthritis.Rheumatoid ArthritisDrug: Methotrexate;Drug: Intraarticular betamethasone;Drug: Cyclosporine/placebo-cyclosporineHvidovre University HospitalNULLCompleted18 Years75 YearsBoth160Phase 4Denmark